CNS & Neurological Disorders - Drug Targets’ Post

Brilliant review by author: [email protected] Centre for Translational Pharmacology, School of Molecular Biosciences, The Advanced Research Centre, University of Glasgow, Glasgow, UK. e-mail: [email protected] Ancient Egyptians treated airway disease by breathing the smoke from a herb containing a muscarinic receptor antagonist. With a better understanding of the receptor’s biology and drug design, these medications offer promise for other hard-to-treat neurological diseases, including Alzheimer’s disease. https://lnkd.in/gWECg2VG The effectiveness of KarXT drug in treating the symptoms of patients with schizophrenia who experience acute psychosis was upheld in phase III clinical trials EMERGENT-2 (NCT04659161) and EMERGENT-3 (NCT04738123). KarXT studies have now been extended in phase III trials to evaluate efficacy in correcting psychosis in patients with Alzheimer disease (NCT06126224).

The December 2024 Highlighted Trainee Author for Molecular Pharmacology is Elijah Ullman, PhD, who recently earned his PhD from Emory University School of Medicine. He believes that his research embiggens the pharmacological toolset and knowledge base for allosteric modulation. Research shows that 30 years after the discovery of the NMDA receptor, there are still many mysteries to discover about how to modulate this essential target. Understanding all the ways in which the receptor can be modulated will help further the development of therapeutics for NMDA receptor-associated neurological disorders such as stroke, schizophrenia, and epilepsy. “I hope that this work excites people into continuing to study ion channels at the single-channel level as there are fantastic riches to be explored when studying a single receptor.”   Read more of his work here: https://lnkd.in/eFfyTrFD

👁️ 💉 I'm thrilled to finally share the results of a long and rewarding journey! Our systematic review, titled "Therapeutic role of erythropoietin in methanol-induced optic neuropathy: a systematic review," has been published in DARU Journal of Pharmaceutical Sciences (Q2, IF: 2.6, part of Springer Nature). Our systematic review systematically analyzed 11 studies involving 212 participants with methanol-induced optic neuropathy (MION). Erythropoietin (EPO) treatment improved visual acuity in most patients, with outcomes ranging from minor improvements to full vision recovery. However, the concurrent use of corticosteroids in many studies limits the ability to isolate EPO's independent effect. These findings underscore EPO’s potential for treating MION while highlighting the need for larger, controlled trials to establish its efficacy as a standard treatment. This project has been a truly enriching experience—full of challenges, growth, and collaboration. I want to take a moment to thank the incredible team behind this work. Dr.Ali Jafarizadeh, Dr.neda feizi, Dr.Mahsa Nabiei, and Dr.Shadi Farabi Maleki—your expertise and dedication truly made this possible. I feel so fortunate to have worked alongside such talented colleagues. #OpticNeuropathy #Neuroprotection #Erythropoietin #MethanolToxicity

In this webinar on 30 September, hosted by Drug Discovery World and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, MD PhD, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. What you will learn: - Where are the breakthroughs in neuroscience research? - How are advanced technologies proving beneficial to drug discovery and development? - How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity? There's still time to register!

𝗧𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗖𝗕𝗗 𝗶𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 🔬 Have you ever wondered about CBD’s intriguing role in ion channel modulation? Dive into the world of pre-clinical drug discovery with our latest blog series, where we unravel the intricate relationship between CBD and ion channels. 📝 Join Marc Rogers as he explores exciting research on CBD. His blog shines a light on CBD´s therapeutic promise. As current research and pharmaceutical efforts focus on this compound, understanding its effects on ion channels becomes crucial. What insights await you? 𝗡𝗲𝘂𝗿𝗼𝗻𝗮𝗹 𝗡𝗮𝗩𝟭.𝘅 𝗖𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Discover how CBD inhibits these channels, affecting neuronal function. 𝗢𝘁𝗵𝗲𝗿 𝗻𝗲𝘂𝗿𝗼𝗻𝗮𝗹 𝘃𝗼𝗹𝘁𝗮𝗴𝗲-𝗴𝗮𝘁𝗲𝗱 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Explore how CBD modulates various voltage-gated channels in the nervous system. 𝗦𝗸𝗲𝗹𝗲𝘁𝗮𝗹 𝗮𝗻𝗱 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗺𝘂𝘀𝗰𝗹𝗲 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Learn about CBD’s impact on muscle function. 𝗟𝗶𝗴𝗮𝗻𝗱-𝗴𝗮𝘁𝗲𝗱 𝗶𝗼𝗻𝗼𝘁𝗿𝗼𝗽𝗶𝗰 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝘀: Uncover how CBD influences these receptors. 𝗖𝗕𝗗 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝘀𝗶𝘁𝗲𝘀 𝗮𝗻𝗱 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀: Get insights into the molecular interactions. 📚 Learn more in the Pre-clinical Drug Discovery Blog. Read more: https://ow.ly/fg6g50RBVNL #DrugDevelopment #PreclinicalStudies #IonChannels #CBDResearch #Neuroscience #Cardiology

🌟 Exciting Research Update! 🌟 I am thrilled to share our recently published systematic review on the application of erythropoietin in methanol-induced optic neuropathy. This study has been a significant journey for my colleagues and me, filled with numerous challenges and learning opportunities. Erythropoietin (EPO) is primarily known for its role in red blood cell production, but emerging evidence suggests its potential neuroprotective effects, particularly in the context of optic nerve injuries caused by methanol toxicity. Our review meticulously examines the existing literature, aiming to elucidate the mechanisms through which EPO may mitigate neuronal damage and promote recovery in affected patients. I would like to express my sincere appreciation to my esteemed colleague, Ali Jafarizadeh , for his exemplary teamwork and professionalism throughout our collaborative efforts. I invite you to read our article and explore how EPO could pave the way for innovative treatment strategies in methanol-induced optic neuropathy. Your feedback and thoughts would be greatly appreciated! #Research #Neuropharmacology #Erythropoietin #OpticNeuropathy #SystematicReview #MethanolToxicity #Ophthalmology #Retina

👁️ 🧪 Thrilled to share the fruits of a long and enriching journey—our systematic review titled "Therapeutic role of erythropoietin in methanol-induced optic neuropathy: a systematic review"—now published in DARU J Pharm Sci (Q2, IF: 2.6, part of Springer Nature). This project has been years in the making, marked by dedication, challenges, and invaluable teamwork. Methanol-induced optic neuropathy (MION) remains a critical therapeutic challenge, with no established treatment. Erythropoietin (EPO), primarily known for its hematopoietic role, shows promise in improving visual outcomes due to its potential neuroprotective effects. Our review analyzes 11 studies involving 212 participants, revealing significant visual acuity improvements in most cases treated with EPO. Despite improvements in visual outcomes observed with EPO, the simultaneous use of corticosteroids in many studies complicates the assessment of its independent therapeutic role. Larger, controlled trials are crucial to fully elucidate its potential as a standard treatment for MION. This work would not have been possible without the extraordinary collaboration and expertise of my esteemed colleagues, Dr. Hadi Vahedi, Dr. neda feizi, Dr. Mahsa Nabiei, and Dr. Shadi Farabi Maleki; Your professionalism and dedication have been the backbone of this research, and I am deeply grateful for the opportunity to work alongside you. I invite you all to explore our findings: 🌐 Link : https://lnkd.in/epP8gNcx #Research #OpticNeuropathy #Neuroprotection #Collaboration #Erythropoietin #MethanolToxicity

One of the earlier in vitro #Alzheimer's disease studies conducted by InMed in collaboration with UBC Faculty of Pharmaceutical Sciences' Dr. Ujendra Kumar demonstrated how InMed's compounds reduced amyloid toxicity and tau protein expression while enhancing neuronal cell growth, all considered to be important targets in the potential treatment of #neurodegenerative diseases such as #Alzheimers. These promising studies led to the launch of INM-901, a drug candidate being developed for the treatment of Alzheimer's disease. Scientific poster here: https://ow.ly/mBRn50SBTNN $INM #neuroscience #pharma

Can Lumencor's all-optical "patch-clamping" system (VOLTA) provide more and better data than traditional micro-electrode arrays (MEAs)? Pfizer thinks so and demonstrated as much! Check out the recent paper published in European Journal of Pharmacology below.

Abstract: This Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves into the characterization and potential uses of crystalline forms of tryptamine derivatives. These innovations signify significant progress in drug delivery systems, neurostimulation methods, and the therapeutic use of psychedelic compounds, potentially revolutionizing the treatment of psychological and neurological disorders. https://lnkd.in/gfXa48bS - #drugdevelopment #science #medicinalchemistry #drugdiscovery #medicine #drugspharmaceuticals #oncology #drug